Pfizer, Inc. News

Do you have an interest in the products developed by Pfizer, Inc., or are you interested in the performance of the company? If you are you should register for the free Pfizer, Inc. news email from Wiser. Pfizer, Inc. is an American-based pharmaceutical company that researches, develops and manufactures medicines and vaccines. The products developed by the company are used all over the world. They include leading brands like Lipitor, Zithromax and Viagra. The company was founded in 1849 and today is one of the largest pharmaceutical companies in the world. Its current chairman and CEO is Ian Reed. Most analysts expect Pfizer, Inc. to expand through acquisitions over the coming years. The Wiser daily Pfizer, Inc. news email covers this news as well as analysis on the performance of the company, and details about its products. These articles come from the best sources around the web and are delivered in a comprehensive but simple to use format. Sign up today.

Recent Pfizer, Inc. News Coverage
 
Your Weekly Recommendations Saturday, February 25, 2017
 
Recommended for you
UPDATE 1-Pfizer subpoenaed in U.S. over patient assistance plans
Reuters
Pfizer Subpoenaed in DOJ Investigation of Drugmaker Charity Connections
Bloomberg • Robert Langreth
GOP Tax Leader Rallies Conservative Support for Levy on Imports
Heritage Foundation • Josh Siegel
A Dividend Portfolio Built From The World's Best Dividend ETFs
Seeking Alpha • Etf Monkey
Truxima Fires The Starting Gun In Biosimilar Race To The Bottom
Seeking Alpha • E.P. Vantage
The Risks Keep Rising For Roche's Hemophilia Hope
Seeking Alpha • E.P. Vantage
Early Statin Start After Stroke No Better for Outcomes
MedPage Today • Crystal Phend
Tim Mullaney: The GOP’s real Obamacare problem: it taxes the near-1%
MarketWatch • Tim Mullaney
European advisory committee positive actions
Seeking Alpha • Seeking Alpha
The Demise Of The Erectile Dysfunction TV Ads
Forbes • Contributor, John Lamattina
 
Recommended for You
Economic Policy, Health Care Industry
UPDATE 1-Pfizer subpoenaed in U.S. over patient assistance plans
Reuters
Feb 24 (Reuters) - Pfizer Inc said it received subpoenas from the U.S. Attorney's Office for the District of Massachusetts related to its support for organizations that provide financial help to Medicare patients.
Share
Gilead Sciences, Medicare
Pfizer Subpoenaed in DOJ Investigation of Drugmaker Charity Connections
BloombergRobert Langreth
Pfizer Inc. said that it received two subpoenas from the U.S. Attorney’s office in Massachusetts related to charities that help Medicare patients afford co-payments for drugs, the latest company to disclose involvement in the probe. The New York-based drugmaker said in a...
Share
Pfizer, Inc., Small Business
GOP Tax Leader Rallies Conservative Support for Levy on Imports
Heritage FoundationJosh Siegel
Rep. Kevin Brady, R-Texas, sought to convince conservative activists on Friday to rally behind a plan from House Republican leaders to tax imports instead of exports. Brady, chairman of the Ways and Means Committee, argues along with House Republican leadership that the...
Share
Pfizer, Inc., Wells Fargo & Co.
A Dividend Portfolio Built From The World's Best Dividend ETFs
Seeking AlphaEtf Monkey
Summary While my work here on primarily revolves around ETFs, I am well aware that many investors prefer to build their portfolio primarily or exclusively using individual stocks. In particular, when it comes to dividend investing, might there be an opportunity to...
Share
Health Finance, Pfizer, Inc.
Truxima Fires The Starting Gun In Biosimilar Race To The Bottom
Seeking AlphaE.P. Vantage
With no patent dance or odd nomenclature requirements, and more potential for switching, Europe's first cancer biosimilar is a go. Celltrion's Truxima, a version of Roche's (OTCQX:RHHBF, OTCQX:RHHBY) Rituxan, was recommended for EU approval in December, and yesterday the marketing partner Mundipharma...
Share
Health Finance, Pfizer, Inc.
The Risks Keep Rising For Roche's Hemophilia Hope
Seeking AlphaE.P. Vantage
Roche's (OTCQX:RHHBF, OTCQX:RHHBY) rising haemophilia star emicizumab is far from untarnished on the safety front, but news of a patient death in its ongoing pivotal programme takes concerns to a new level. The big question is whether the apparent thrombosis risk is...
Share
Cardiovascular Disease, Employee Benefits
Early Statin Start After Stroke No Better for Outcomes
MedPage TodayCrystal Phend
HOUSTON -- Statin therapy from day 1 for acute stroke patients with high cholesterol or already on one did not improve outcomes, the ASSORT randomized trial showed. That early start to lipid-lowering treatment did not shift modified Rankin Scale scores compared with...
Share
Finance, Health Insurance
Tim Mullaney: The GOP’s real Obamacare problem: it taxes the near-1%
MarketWatchTim Mullaney
Getty Images To read most press accounts of the travails of Republican senators and representatives confronting town halls full of sick people demanding they keep the Affordable Care Act on the books, you might think the party has a problem with health...
Share
Novartis AG, Pfizer, Inc.
European advisory committee positive actions
Seeking AlphaSeeking Alpha
The European Medicines Agency's Committee for Medical Products for Human Use (CHMP) is churning out recommendations today. Positive opinions: Expanded use of Novartis' (NYSE:NVS) Mekinist (trametinib) and Tafinlar (debrafenib) in advanced NSCLC with BRAF V600 mutation. Expanded use of Gilead Sciences' (NASDAQ:GILD)...
Share
Advertising Industry, Brand Management
The Demise Of The Erectile Dysfunction TV Ads
ForbesContributor, John Lamattina
“Daddy, what’s erective dysfunction?”
Share